Haemonetics (HAE) closed the last trading session at $84.21, gaining 1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $112.17 indicates a 33.2% upside potential.The average comprises six short-term price targets ranging from a low of $94 to a high of $125, with a standard deviation of $10.87. While the lowest estimate indicates an increase of 11.6% from the current price level, t ...

Haemonetics (HAE) has been beaten down lately with too much selling pressure. While the stock has lost 5.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator th ...

Haemonetics Corporation (HAE) , a global medical technology company, has introduced a limited market release of VASCADE MVP XL mid-bore venous closure device. The device comes with innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis. The latest development is expected to help Haemonetics grab opportunities in the growing vascular closure solutions space. About VASCADE MVP XL VASCADE MVP XL system is designed for "mid-bore" multi-access femo ...

BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis. ...

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets c ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. It also includes access to the Zacks Style Scores. What are ...

Haemonetics (HAE) has been gaining from business growth within Plasma, Hospital and Hemostasis Management. Its new launches also aid growth. The stock carries a Zacks Rank #1 (Strong Buy) currently. Haemonetics’ Plasma revenues grew 6% in the fourth quarter of fiscal 2024, driven primarily by disposable volume and software. The collections environment in the United States continued to be favorable, with disposables growing 4% in the quarter and 13% in fiscal 2024. The company is gaining from the newly-compl ...

With healthcare services being essential many medical stocks are often seen as a defensive hedge in times of economic uncertainty but can be overlooked when markets are doing well. Keeping this scenario in mind, today’s better-than-expected CPI data for May sparked a rally among broader indexes and amid the inflationary optimism, investors will still want to consider several top medical stocks that were added to the Zacks Rank #1 (Strong Buy) list this week. Medical-Outpatient and Home Healthcare Currently, ...

Here is a stock with buy rank and strong momentum characteristics for investors to consider today, June 6th: Haemonetics Corporation (HAE) : This healthcare company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days. Haemonetics’ shares gained 14.2% over the last three months compared with the S&P 500’s advance of 3.3%. The company possesses a Momentum Score of B. See the full list of top ranked stocks here Learn more about the ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Howmet Aerospace Inc. (HWM) : This company that provides advanced engineered solutions for the aerospace and transportation sectors has seen the Zacks Consensus Estimate for its current year earnings increasing 9.6% over the last 60 days. Ligand Pharmaceuticals Incorporated (LGND) : This biopharmaceutical company has seen the Zacks Consensus Estimate for its current year earnings increasing 3.3% over the last 60 days. Matson, Inc. (MAT ...